END-VOC Ending Covid 19 Variants of Concern Through Cohort Studies: End-voc
- Coordinator
- University College London, United Kingdom
- Runs
- 1 May 2022 to 31 October 2025
- Status
- Running
- EU funding
- €10.5m
- Total cost
- €10.5m
- Partners
- 25 organisations in 18 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101046314
What the project is doing
In the project's own words, from its summary on CORDIS.
The END-VOC consortium will support the European and global response to the COVID-19 pandemic and Variants of Concern (VOC) through well characterised cohorts and linked with existing European and international initiatives. END-VOC consists of 19 partners in Europe (UK, Spain, Italy, Germany, Netherlands, Norway, Italy), South America (Brazil and Peru), Africa (Mozambique, South Africa, Nigeria and 13 ANTICOV African countries), Middle East (Palestine) and Asia (India, Pakistan, Philippines) with a focus on countries affected by VOCs and VOIs.
We will elucidate the global circulation of the current and emerging SARS-CoV-2 VOCs and their characteristics, including transmissibility, pathogenicity and propensity to cause reinfection, to support best control strategies and the development of diagnostics; evaluate the impact of VOCs on the effectiveness of different vaccines and vaccination strategies; and assess the implications of VOCs on the choice of optimal treatment options.
END-VOC will also investigate how VOCs alter long-term post-infection sequelae and where new VOCs emerge within hosts using our clinical cohorts. We will inform future preparedness and response working closely with international and national public health organisations and existing cohort consortia. Specific beyond state-of-the-art components of END-VOC include the use of novel phylogenetic prediction tools and mathematical modelling; generation of powerful cohorts through sentinel surveillance in low and middle income settings and cohorts of travellers to increase our global reach; use of novel predictive modelling of clinical outcomes by VOC and comorbidity/treatment and evaluation of differences in natural and vaccine immunity by VOC; antiviral screening models within cohorts and an artificial intelligence driven tool for the prediction of long COVID.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| University College London | London | United Kingdom | Coordinator |
| Fiotec-Fundacao Para O Desenvolvimento Cientifico E Tecnologico Em Saude | Rio De Janeiro | Brazil | Third party |
| Fundacao Oswaldo Cruz | Rio De Janeiro | Brazil | Participant |
| Drugs for Neglected Diseases Initiative Fondation | Geneve | Switzerland | Participant |
| Universite De Geneve | Geneve | Switzerland | Participant |
| Universitatsklinikum Heidelberg | Heidelberg | Germany | Participant |
| Fundacio Institut Universitari Pera La Recerca a L'atencio Primaria De Salut Jordi Gol I Gurina | Barcelona | Spain | Participant |
| Fundacion Privada Instituto De Salud Global Barcelona | Barcelona | Spain | Participant |
| Hospital Clinic De Barcelona | Barcelona | Spain | Third party |
| Institut Catala De La Salut | Barcelona | Spain | Third party |
| Institut De Investigacio En Ciencies De La Salut Germans Trias I Pujol | Badalona Barcelona | Spain | Participant |
| Public Health Foundation of India | New Delhi | India | Participant |
| Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico | Milano | Italy | Participant |
| Universita Degli Studi Di Milano | Milano | Italy | Participant |
| Laboratoire National De Sante | Dudelange | Luxembourg | Participant |
| Fundacao Manhica | Vila Da Manhica Maputo | MZ | Participant |
| Nigeria Centre for Disease Control and Prevention | Abuja | NG | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Folkehelseinstituttet | Oslo | Norway | Participant |
| University of the Philippines System | Quezon City | PH | Participant |
| Dopasi Foundation | Islamabad | PK | Participant |
| Arab American University | Jenin | PS | Participant |
| Fundacao Gimm - Gulbenkian Institute for Molecular Medicine | Lisboa | Portugal | Participant |
| African Field Epidemiology Network Lbg | Kampala | UG | Third party |
| University of Washington | Seattle Wa | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI